Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23

You may also be interested in...



RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway

TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway

RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway

Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.

RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway

TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway

Related Content

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel